Cough And Cold Preparations Global Market Report 2023 – By Type (Bronchodialators, Anticholinergic, Pulmonary Antihypertensives), By Drug Type (Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Other Types), By Dosage Type (Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Other Dosage Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores) – Market Size, Trends, And Global Forecast 2023-2032

Regenerative medicine for cartilage refer to a medication used during surgery to repair damaged cartilage in the knees using body-produced cells that can create cartilage. A biopsy is required to collect chondrocytes (cells that produce cartilage), which are then multiplied in a lab before being implanted into the injured area during surgery. The main types of regenerative medicine for cartilage are cell-based and non-cell-based. The type of treatment includes palliative and intrinsic repair stimulus among others that are used by ambulatory surgical centers, hospitals and clinics, and surgical centers. The regenerative medicine for cartilage is used for hyaline cartilage repair and regeneration, elastic cartilage repair and regeneration, and fibrous cartilage repair and regeneration. The global regenerative medicine for cartilage market is segmented - 1) By Treatment Modality: Cell-Based, Non-Cell-Based 2) By Treatment Type: Palliative, Intrinsic Repair Stimulus, Other Treatment Types 3) By Site: Knee Cartilage Repair, Ribs, Other Sites 4) By Application: Hyaline Cartilage Repair and Regeneration, Elastic Cartilage Repair and Regeneration, Fibrous Cartilage Repair and Regeneration 5) By End-Use: Ambulatory Surgical Centers, Hospitals & Clinics, Surgical Centers, Other End-Users The global regenerative medicine for cartilage market size will grow from $5.28 billion in 2022 to $5.82 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the regenerative medicine for cartilage is expected to grow to $7.72 billion in 2027 at a CAGR of 7.3%. The growing incidence of osteoarthritis across the globe will drive the regenerative medicine for cartilage market. Osteoarthritis is a degenerative joint disorder that mostly attacks the articular cartilage. According to the Arthritis Foundation, degenerative joint disease disorders such as osteoarthritis will impact at least 130 million individuals around the globe by 2050. Some of the most commonly used treatments for osteoarthritis are autologous chondrocyte implantation and scaffold implants. Thus, the increasing incidence of osteoarthritis is expected to drive the demand for growth of the regenerative medicine for cartilage market. Major players in the regenerative medicine for cartilage market are B. Braun Melsungen AG, Zimmer Biomet Holdings Inc., Vericel Corporation, Stryker Corporation, Smith & Nephew PLC, Arthrex Inc., CONMED Corporation, Collagen Solutions PLC, BioTissue Technologies, CellGenix, Osiris Therapeutics Inc., and DePuy Synthes. The high cost of regenerative medicine therapies is one of the major factors limiting the growth of the market for regenerative medicine for cartilage. The average cost for knee replacement is around $4,500 to $8,400, while the average cost of cartilage repair procedures is around $18,000, depending on the country where the procedure is being performed. Such high prices discourage individuals to resort to cartilage repair therapies and, in turn, result in a lower preference for these procedures. Tissue engineering and stem cell therapy are emerging trends in regenerative medicine for the cartilage market. The growth of tissue engineering technology has given hope for the regeneration of cartilage. Stem cell therapy is gaining attention with its advantages over traditional orthopaedic treatments. Stem cell therapy helps to reduce knee pain and improves knee cartilage regeneration and repair. For instance, growth factors in the form of platelet-rich plasma (PRP) therapy are injected to promote tissue regeneration effectively. Companies operating in the market are continuously focusing on introducing new technologies to survive in the regenerative medicine for cartilage market. In September 2020, Smith & Nephew plc, a UK-based multinational medical equipment manufacturing company, acquired the orthopaedics business of Integra LifeSciences Holdings Corporation for an amount of $240 million. The acquisition is expected to stimulate growth in Smith & Nephew’s extremities business by adding a targeted sales channel, a portfolio of compatible upper and lower extremities, shoulder replacements, and an intriguing new product pipeline. Integra LifeSciences Holdings Corporation is a US based medical device manufacturing company specializing in solutions in extremities orthopedics, neurosurgery, and regenerative technologies, all geared toward reducing clinician uncertainty. Europe was the largest region in regenerative medicine for cartilage in 2022. The regions covered in the regenerative medicine for cartilage market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the regenerative medicine for cartilage market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The regenerative medicine for cartilage market consists of sales of cartilage regeneration, platelet-rich plasma (PRP), and prolotherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The regenerative medicine for cartilage market research report is one of a series of new reports from The Business Research Company that provides regenerative medicine for cartilage market statistics, including regenerative medicine for cartilage industry global market size, regional shares, competitors with a regenerative medicine for cartilage market share, detailed regenerative medicine for cartilage market segments, market trends and opportunities, and any further data you may need to thrive in the regenerative medicine for cartilage industry. This regenerative medicine for cartilage market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Telemedicine services are health care services provided via video chat, phone calls, and text messages. Patients can use telemedicine for physical examination as well as to ask questions regarding health concerns. The main types of telemedicine services are web-based, cloud-based, and on-premises. Cloud-based solutions provide healthcare providers financial, logistical, and functional advantages over in-house client-server systems. Cloud computing provides cost flexibility as well as the potential for cost reductions. The different technologies include store and foreward, real time and is used in teleradiology, telepsychiatry, telepathology, teledermatalogy, telecardiology. The global telemedicine services market is segmented - 1) By Technology outlook: Store and Foreward, Real time 2) By Application: Teleradiology, Telepsychiatry, Telepathology, Teledermatalogy, Telecardiology 3) By Type: Web-based, Cloud-based, On-premises The global telemedicine services market size will grow from $103.06 billion in 2022 to $131.75 billion in 2023 at a compound annual growth rate (CAGR) of 27.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global telemedicine services is expected to grow to $262.33 billion in 2027 at a CAGR of 18.8%. Rising cases of COVID 19 infections across the globe is driving the telemedicine services market. As of December 2020, the total number of active cases around the world is around 19,649,961 million and expected to increase until the availability of vaccines. Telemedicine services will provide healthcare services to the COVID 19 affected people as they cannot step out to avail the services. Rising cases of COVID 19 infections across the globe is expected to boost the demand for the telemedicine services market. Major players in the telemedicine services market are AMD Global Telemedicine Inc., Philips Healthcare, Cisco Systems, Inc., McKesson Corporation, Allscripts Healthcare Solutions Inc., GE Healthcare Ltd., Cerner Corporation, BioTelemetry Inc. and Teladoc. Breach in the data makes the patients uncomfortable on sharing personal information that would help the physicians to diagnose the patients' health, affecting the telemedicines market negatively. Telemedicine services are provided online or through calls and might not have much security for storing the data, or in some cases the telemedicine companies may use third-party servers to store the customer data to cut down the maintenance cost, which might lead to easy data breaches. For instance, according to Hippa Journal, the official publication of the American Health Information Management Association, the Office for Civil Rights (OCR) of the Department of Health and Human Services (HHS) received 347 reports of healthcare data breaches involving 500 or more records between January 1, 2022, and June 30, 2022. Telemedicine is increasingly being accepted and insurance companies and government-regulated health care programs are increasingly covering telemedicine services in their plans. The governments are probing companies to make changes to the policies to cover the services under their schemes. For instance, in March 2020, in response to the coronavirus outbreak, the US government announced that private insurers will be covering the cost of coronavirus testing and telemedicine services for patients. In April 2022, Patient Square Capital, a US-based healthcare investment firm, acquired SOC Telemed for an undisclosed amount. Through this acquisition, Patient Square Capital will help SOC Telemed to be well-positioned to fulfill the expanding demands of patients, clinicians, and our hospital partners. SOC Telemed is US-based company specializing in telemedicine technology and solutions. North America was the largest region in the telemedicine services market in 2022. Asia-Pacific was the second largest region in global telemedicine services market share. The regions covered in the global telemedicine services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the telemedicine services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The telemedicine services market includes revenues earned by entities by providing teleneuropsychology, telenursing, telepharmacy, and telerehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The telemedicine services market research report is one of a series of new reports from The Business Research Company that provides telemedicine services market statistics, including telemedicine services industry global market size, regional shares, competitors with a telemedicine services market share, detailed telemedicine services market segments, market trends and opportunities, and any further data you may need to thrive in the telemedicine services industry. This telemedicine services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Precision medicine refers to a type of medication that prevents, detects, or treats disease using knowledge about a person's own genes or proteins. In order to choose a treatment that may be most effective for a person, precision medicine considers their genetics, environment, and lifestyle. The main technologies involved in precision medicine are bioinformatics, big data analytics, drug discovery, gene sequencing, companion diagnostics, and others. Bioinformatics technologies involve the application of computational tools to organize, analyze, understand, visualize and store information associated with biological macromolecules. It is used in oncology, respiratory diseases, central nervous disorders, immunology, genetic diseases, others and is implemented in various sectors such as hospitals and clinics, pharmaceuticals, diagnostic companies, healthcare, and IT firms, among others. The global precision medicine market is segmented - 1) By Technology: Big Data Analytics, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Other Technologies 2) By Application: Oncology, Respiratory Diseases, Central Nervous System Disorders, Immunology, Genetic Diseases, Other Applications 3) By End-User: Hospitals And Clinics, Pharmaceuticals, Diagnostic Companies, Healthcare And IT Firms, Other End-Users The global precision medicine market size will grow from $83.43 billion in 2022 to $95 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The precision medicine market size is expected to grow to $157.26 billion in 2027 at a CAGR of 13.4%. The rising prevalence of cancer is projected to fuel the growth of the precision medicine market in the coming years. Cancer is one of the main causes of death worldwide, with one out of every five individuals developing cancer at some point in their lives. Precision medicine in cancer entails analyzing DNA from tumors to find mutations or other genetic abnormalities that cause cancer. Physicians may therefore be able to choose a treatment for a specific patient's cancer that best fits, or targets, the tumor DNA alterations. For instance, according to recent predictions from the International Agency for Research on Cancer (IARC), the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020. Therefore, the rising prevalence of cancer drives the growth of the precision medicine market. Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc., Quest Diagnostics, Thermo Fisher Scientific Inc., Pfizer, Bristol-Myers Squibb, Merck & Co. Inc., Tepnel Pharma Services, Abbott Laboratories, Takeda Pharmaceutical Company Ltd., and Eli Lilly and Company. The development of novel precision medicine for pancreatic cancer is shaping the precision medicine market. Extensive research is being undertaken on different approaches to develop precision medicines for pancreatic cancer. For instance, in October 2020, Scientists from the University of Glasgow announced the development of a novel precision medicine approach for treating the damaged DNA in the cancer cells of pancreatic cancer patients. The team used grown cells from the lab, and replicas of patients' tumors, to find molecular markers, which were used in the prediction and response to several drugs, targeting DNA damage. The researchers tested certain markers using multiple drugs, also developed a strategy that is taken forward into a clinical trial. The trial will help doctors and researchers to predict which patient will respond to one of these drugs, either alone or in combination. In April 2021, Servier Laboratories, a France-based pharmaceutical company acquired Agios Pharmaceuticals Inc.,’s commercial, clinical, and research-stage oncology portfolio for an undisclosed amount. The acquisition of Servier Laboratories is focused on strengthening its commercial presence in the malignant technology market and provides the potential for long-term growth into the solid tumor space. The transaction includes marketed oncology precision medicine in malignant technology, clinical oncology pipeline with multiple early-stage and phase-3 assets. Agios Pharmaceuticals is a US-based company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. North America was the largest region in the precision medicine market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precision medicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The precision medicine market consists of sales of imatinib, personalized medicine, and individualized medicine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The precision medicine market research report is one of a series of new reports from The Business Research Company that provides precision medicine market statistics, including precision medicine industry global market size, regional shares, competitors with a precision medicine market share, detailed precision medicine market segments, market trends and opportunities, and any further data you may need to thrive in the precision medicine industry. This precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nanomedicine refers to the use of nanotechnology in medicine. It is described as substances with a size between 1 and 100 nanometers that, in the end, should be able to precisely target tumour cells or important immune cells. Nanomedicine is an important instrument that enables personalized, targeted, and regenerative medicine by delivering improved new drugs, treatments, and implantable devices to clinicians and patients. The main types of nanomedicine are nanoparticles, nanoshells, nanotubes, nanodevices, and others. Nanoparticles are a type of ultrafine particles usually between 1 and 100 nanometers in diameter used in making medicine and drugs. The different forms of modality include diagnostics, treatments and are used in clinical oncology, infectious diseases, clinical cardiology, orthopedics, others. The global nanomedicine market is segmented - 1) By Type: Nanoparticles, Nanoshells, Nanotubes, Nanodevices, Other Types 2) By Modality: Diagnostics, Treatments 3) By Application: Clinical Oncology, Infectious Diseases, Clinical Cardiology, Orthopedics, Other Applications The global nanomedicine market size will grow from $253.34 billion in 2022 to $287.42 billion in 2023 at a compound annual growth rate (CAGR) of 13.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the nanomedicine is expected to grow to $487.69 billion in 2027 at a CAGR of 14.1%. The rising burden of complex and chronic diseases across the globe is expected to contribute to the growth of the nanomedicine market in the forecast period. Nanomedicine is increasingly being used in treating chronic diseases including cardiovascular disorders, diabetes, cancer, dementia, and others where it helps in the fast metabolism of drugs in the body. According to the international federation of Alzheimer's associations, Alzheimer's Disease International, more than 50 million people are suffering from dementia globally, and is projected to double every 20 years, which will reach 80 million by 2030 and 152 million by 2050. In 2020, the total cancer burden in the world increased to 19.3 million new cases and is predicted to rise to 28.4 million new cancer cases in 2040. This increasing burden of chronic diseases is expected to propel the demand for effective therapeutics treatment based on nanomedicine, thus driving the growth of nanomedicine market. Major players in the nanomedicine market are Pfizer Inc., Nanotherapeutics Inc., NanoViricides Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, Merck AG, Ablynx NV, F. Hoffmann-La Roche AG, Nanospectra Biosciences, GE Healthcare, Gilead Sciences Inc., Novartis AG, Amgen Inc., and Sanofi. The 4D Nanomedicine is a key trend gaining popularity in the nanomedicine market. 4D nanomedicine is used in medical procedures for safer treatment with nanoparticles. 4D nanomedicine is made with biodegradable and biocompatible nanoalloys that do not accumulate in the body, thus, limiting the side effects. The 4D nanomedicine is accepted as a fundamental development in the treatment and diagnosis of cancer. For instance, in 2020, a research team from The Department of Chemical Sciences, University of Padua investigated and confirmed the effectiveness of inorganic 4D nanoparticles in the biomedical field. 4D nanomedicine offers several advantages to the biomedical field including reduced side effects in a living organism, minimal environmental impact, improved quality of care, and spontaneous effect. In August 2021, Sanofi S.A., a France-based pharmaceutical and healthcare company, acquired Translate Bio, Inc., for $3.2 billion. Under this acquisition, Sanofi accelerates the creation of currently approved Sanofi vaccination programs and opens up the possibility of investigating additional therapeutic fields. The mRNA Center of Excellence at Sanofi is being established more quickly. Full integration strengthens US talent in a promising new technology and improves drug formulation capabilities. Exploring the potential of this technology to create both best-in-class vaccines and treatments is further advanced by Translate Bio's addition of an mRNA technology platform and strong skills to our research. Translate Bio, Inc., is a US-based clinical stage biopharmaceutical company developing a new class of potentially game-changing drugs to treat conditions brought on by protein or gene malfunction or to stop infectious diseases by boosting immune defences. North America was the largest region in the nanomedicine market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanomedicine market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nanomedicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The nanomedicine market consists of sales of gold, silica, iron oxide, polymeric, liposomes, and micelles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The nanomedicine market research report is one of a series of new reports from The Business Research Company that provides nanomedicine market statistics, including nanomedicine industry global market size, regional shares, competitors with a nanomedicine market share, detailed nanomedicine market segments, market trends and opportunities, and any further data you may need to thrive in the nanomedicine industry. This nanomedicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A medical cart refers to typically portable equipment that is configured with drawers, colors, locking mechanisms, and other characteristics to help them store and organize materials and equipment used in various medical operations. The medical cart is used in hospitals to help medical professionals in transporting medical supplies by using trolleys. The main types of medical carts are emergency carts, anesthesia carts, procedure carts, telemedicine carts, and other types. The emergency carts refer to drawers used primarily for cardiac pulmonary resuscitation and emergency conditions in all hospital units. The material types include metal, plastic, and other types. These are used in hospitals, physician offices, and other end users. The global medical carts market is segmented - 1) By Type: Anesthesia Carts, Emergency Carts, Procedure Carts, Telemedicine Cart, Other Type 2) By Material Type: Metal, Plastic, Others Type 3) By End User: Hospitals, Physician Offices, Other End User The global medical carts market size grew from $2.06 billion in 2022 to $2.34 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global medical carts is expected to grow to $3.95 billion in 2027 at a CAGR of 13.9%. The rising adoption of electronic health records (EHR) is expected to propel the growth of the medical cart market going forward. An electronic health record (EHR) is an electronic version of a patient's medical history that is kept up to date. Medical carts with batteries can travel with healthcare professionals and improves EHR accessibility. For instance, according to Health IT, a US-based organization that represents and serves all types of hospitals and health care networks, as per the data 2019-21 shows that about 86% of non-federal general acute care hospitals have adopted a certified electronic health record (EHR). Therefore, the rising adoption of electronic health records (EHR) is driving the growth of the medical carts market. Major players in the market are ITD GmbH, Advantech Co. Ltd., Harloff Manufacturing Co, AFC Industries, Midmark Corporation, The Bergmann Group, Capsa Healthcare, Jaco Inc., Waterloo Healthcare, Ergotron Inc., The Bergmann Group, Armstrong Medical Inc., Onyx Healthcare Inc and AMD Global Telemedicine Inc. Product innovation is a key trend gaining popularity in the medical carts market. Major companies operating in the medical carts market are developing new products to strengthen their position in the market. For instance, in December 2021, Advantech, a US-based provider of medical carts, launched the AMiS-30EP clinical pole cart for comfortable positioning and rapid care delivery. This product features four anti-static 4" casters for easy movement on floor surfaces. This furnishes a highly customizable cart solution for use in diverse healthcare environments. In August 2021, Capsa Healthcare, a US-based leader in developing and delivering innovative healthcare solutions, acquired Specialty Carts for an undisclosed amount. Through this acquisition, Capsa has grown steadily through a combination of internal development and the acquisition of complementary product brands and platforms. Specialty Carts is a US-based medical cart manufacturer, primarily for the long-term care industry. North America was the largest region in the medical carts market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical carts market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical carts market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The medical cart market consists of sales ofisolation/infection control carts, medical cart accessories, medical computer carts, medication carts, MRI medical carts and pediatric emergency medical carts. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The medical carts market research report is one of a series of new reports from The Business Research Company that provides medical carts market statistics, including medical carts industry global market size, regional shares, competitors with a medical carts market share, detailed medical carts market segments, market trends and opportunities, and any further data you may need to thrive in the medical carts industry. This medical carts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aromatherapy refers to devices which utilize essential oils extracted from nature, such as plants, either to be inhaled or applied to the body to promote health and well-being. The aroma molecules in essential oils move straight from the olfactory nerves to the brain when inhaled, and affecting the amygdala, the brain's emotional center. Aromatherapy helps in reducing pain, enhances sleep quality, reduces joint pain, reduces stress, and others. The main types of aromatherapy products include equipment and consumables. Aromatherapy equipment refers to electronic or non-electronic device, that breaks down essential oil into molecules and disperses them into air in the form of tiny breathable particles. They are delivered through topical application, areal diffusion, and direct inhalation. They are used for relaxation, skin & hair care, pain management, cold & cough, scar management, insomnia, and others. They are sold through B2B and DTC channels to customers from home use, sap & wellness centers, hospitals & clinics, yoga & meditation centers. The global aromatherapy market is segmented - 1) By Product Type: Consumables, Equipment 2) By Delivery Outlook: Topical Application, Aerial Diffusion, Direct Inhalation 3) By Application: Relaxation, Skin & Hair Care, Pain Management, Cold & Cough, Insomnia, Scar Management, Other Applications 4) By End-Use: Home Use, Spa & Wellness Centers, Hospitals & Clinics, Yoga & Meditation Centers 5) By Distribution Channel: D2C, B2B The global aromatherapy market size grew from $1.77 billion in 2022 to $1.93 billion in 2023 at a compound annual growth rate (CAGR) of 9.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The aromatherapy market size is expected to grow to $2.75 billion in 2027 at a CAGR of 9.2%. Rising stress, anxiety, and depression among people is driving the growth of the aromatherapy market. The COVID-19 pandemic has caused numerous changes in individual lives, including uncertainty, disrupted daily routines, financial strains, and social isolation, leading to increased tension, worry, and sadness. The individuals are looking out for ayurvedic and chemical free methods such as aromatherapy to reduce, anxiety and depression. According to a scientific brief issued today by the World Health Organization (WHO) in March 2022, the global occurrence of anxiety and sadness soared by a staggering 25% in the first year of the COVID-19 pandemic. Therefore, the rising stress, anxiety, and depression among people is expected to boost demand for aromatherapy during forecast period. Major players in the aromatherapy market are doTERRA, Young Living Essential Oils, Edens Garden, Mountain Rose Herbs, Plant Therapy Essential Oils, Rocky Mountain Oils, LLC, Florihana, Falcon, Biolandes, Stadler Form Aktiengesellschaft, Hubmar International, SpaRoom, Now foods, Zija international, and Nu skin. Product innovation is a key trend gaining popularity in the aromatherapy market. The companies are focusing on developing innovative equipment and consumables with greater effectiveness to meet the customer demand and strengthen their business reach. One of the recent developments in aromatherapy is usage of CBD in aromatherapy and diffusers. CBD oil is similar to essential oils, made from the direct extraction of oil from the cannabis plant. It has the potential to provide an even higher degree of treatment, hence extending the therapeutic advantages of essential oils. Adding CBD to the mix produces a whole new level of medicinal value that can be much more soothing, has more profound stress relief, and can help control symptoms like inflammation and pain. In January 2022, Martha Stewart CBD, a brand operated by Canopy Growth, a USA-based provider of cannabis and cannabis-based consumer products, lunched new line of products sleep science CBD cream and Daily De-Stress CBD cream with aroma technology. In January 2022, Mensa Brands, an India-based company specializing in fashion and apparel, home and garden, beauty, and personal care, acquired Florona for an undisclosed amount. This acquisition will help them create a line of aromatherapy bath products and natural skincare and haircare solutions, expand their footprint into new areas, and build a tech-driven global supply chain. Florona is personal care brand involved in providing aromatherapy and natural personal care products. Florona offers over 70 different kinds of natural oils, including diffuser essential oils and cold-pressed carrier oils. Western Europe was the largest region in the aromatherapy market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aromatherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the aromatherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The aromatherapy market consists of revenues earned by entities by providing cosmetic aromatherapy, medical aromatherapy and massage aromatherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The aromatherapy market research report is one of a series of new reports from The Business Research Company that provides aromatherapy market statistics, including aromatherapy industry global market size, regional shares, competitors with an aromatherapy market share, detailed aromatherapy market segments, market trends and opportunities, and any further data you may need to thrive in the aromatherapy industry. This aromatherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The respiratory diseases drugs market consists of sales of respiratory diseases drugs and related services by entities (organizations, sole traders and partnerships) that produce drugs to treat respiratory diseases such as asthma, acute bronchitis, emphysema, cystic fibrosis and other diseases. This industry includes establishments that produce anti-asthmatics and COPD drugs to prevent acute attacks caused by respiratory diseases and cough and cold preparations to treat cough and cold. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex® and Lemsip®. The main types of respiratory diseases drugs are anti-asthmatics and copd drugs, cough and cold preparations. Any medication that relieves the symptoms of asthma is considered an anti-asthmatic drugs. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global respiratory diseases drugs market size is expected to decline from $142.57 billion in 2021 to $154.79 billion in 2022 at a compound annual growth rate (CAGR) of 8.6%. The change in the respiratory diseases drugs market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The respiratory diseases drugs market is expected to reach $292.01 billion in 2026 at a CAGR of 17.2%. During the forecast period, the growth of the respiratory diseases drugs market will be restrained by patent expiration of branded respiratory diseases drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value. Companies in the respiratory drugs market are offering drugs for customized individual treatment for better treatment against respiratory diseases. Personalized medicine, also referred to as precision medicine, aims to provide medical care according to the patient’s individual characteristics and genetic makeup. Precision therapies are increasingly being adopted in the respiratory drugs market as firms increasingly let go of the one-size-fits-all model for common respiratory conditions. Companies such as GSK, Teva Pharmaceuticals and AstraZeneca have already invested in personalized medicine for respiratory issues such as asthma. For example, PTC Therapeutics, is developing a drug, which aims to cater to a respiratory mutation which affects about 10% of the population. Companies manufacturing respiratory drugs are increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators which are objectively measured and evaluated for biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. It can also help predict the drug efficacy faster than conventional clinical endpoints, the point at which an undesired or abnormal effect of the drug is observed indicating withdrawal from therapy. Companies in this market are investing in the development of biomarkers for use in various activities such as tracking drug activity, the pharmacodynamics (relationship between the drug concentration at the site of action and the biochemical and physiological effect) of drugs and to study diseases and treatment pathways. Companies such as Genentech and Janssen are increasingly investing in the use of biomarkers for understanding the efficacy of a potential respiratory drug. For example, Janssen has partnership with U-BIOPRED (unbiased biomarkers in prediction of respiratory disease outcomes), a group in Europe that aims to understand more about severe asthma. Major companies in the respiratory diseases drugs market include Boehringer Ingelheim GmbH, Vertex Pharmaceuticals, AstraZeneca, Pfizer Inc., GlaxosmithKline, Novartis AG, Johnson & Johnson, Reckitt Benckiser Group plc, Mylan N.V., and Sanofi S.A. North America was the largest region in the respiratory diseases drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the respiratory diseases drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the respiratory diseases drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global respiratory diseases drugs market is segmented - 1) By Type: Anti-Asthmatics and COPD Drugs, Cough and Cold Preparations 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

Telemedicine Services Market Definition